Kiniksa Pharmaceuticals Files Form 144 for Security Sale
Ticker: KNSA · Form: 144 · Filed: 2026-04-09T16:02:53-04:00
Sentiment: neutral
Topics: insider-filing, securities-sale, form-144
Related Tickers: KNSA
TL;DR
Kiniksa filing 144 - looks like someone's selling shares.
AI Summary
On April 9, 2026, Kiniksa Pharmaceuticals International, plc filed a Form 144, indicating a proposed sale of securities. The filing was made by Michael R. Megna, associated with the company, whose mailing and business address is in London, United Kingdom.
Why It Matters
This filing signals potential insider selling or a planned divestment of shares by an individual associated with Kiniksa Pharmaceuticals, which could impact market perception.
Risk Assessment
Risk Level: medium — Form 144 filings can indicate insider selling, which may precede a price drop, but the specific details and volume are not yet known.
Key Players & Entities
- Kiniksa Pharmaceuticals International, plc (company) — Subject of the filing
- Michael R. Megna (person) — Reporting person
- 0001730430 (company) — CIK for Kiniksa Pharmaceuticals International, plc
- 0001464583 (person) — CIK for Michael R. Megna
FAQ
What is the purpose of a Form 144 filing?
A Form 144 filing is a notice of proposed sale of restricted securities or control securities.
Who is the reporting person in this filing?
Michael R. Megna is listed as the reporting person.
What is the CIK for Kiniksa Pharmaceuticals International, plc?
The CIK for Kiniksa Pharmaceuticals International, plc is 0001730430.
When was this Form 144 filing accepted?
This Form 144 filing was accepted on April 9, 2026.
What is the business address of Kiniksa Pharmaceuticals International, plc?
The business address is 105 PICCADILLY, SECOND FLOOR LONDON United Kingdom W1J 7NJ.
From the Filing
EDGAR Filing Documents for 0001921094-26-000386 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 144 - Report of proposed sale of securities: SEC Accession No. 0001921094-26-000386 Filing Date 2026-04-09 Accepted 2026-04-09 16:02:53 Documents 1 Document Format Files Seq Description Document Type Size 1 primary_doc.html 144 1 primary_doc.xml 144 3525 Complete submission text file 0001921094-26-000386.txt 5098 Mailing Address 1050 HINGHAM STREET ROCKLAND MA 02370 Business Address Megna Michael R ( Reporting ) CIK : 0001464583 (see all company filings) Type: 144 Mailing Address 105 PICCADILLY, SECOND FLOOR LONDON United Kingdom W1J 7NJ Business Address 105 PICCADILLY, SECOND FLOOR LONDON United Kingdom W1J 7NJ 7814319100 Kiniksa Pharmaceuticals International, plc (Subject) CIK : 0001730430 (see all company filings) EIN. : 981795578 | Fiscal Year End: 1231 Type: 144 | Act: 33 | File No.: 001-38492 | Film No.: 26851546 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)